Affinage

DVL3

Segment polarity protein dishevelled homolog DVL-3 · UniProt Q92997

Length
716 aa
Mass
78.1 kDa
Annotated
2026-04-28
40 papers in source corpus 21 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DVL3 is a cytoplasmic scaffold protein that transduces WNT signals through both canonical (β-catenin) and non-canonical (planar cell polarity) pathways by coupling Frizzled receptors to downstream effectors. In canonical signaling, WNT stimulation triggers CK1-dependent multiphosphorylation of DVL3, producing a conformational switch in the DEP domain that promotes DVL3 detachment from Frizzled and activation of β-catenin stabilization; DVL3 recruits cofactors such as IPMK to the membrane via its PDZ domain, and its protein levels are regulated by ALFY-mediated selective autophagy and AMPK/mTOR-dependent proteasomal turnover (PMID:22940627, PMID:27008544, PMID:23301094). In the non-canonical WNT-PCP branch, FZD3 recruits DVL3 to the membrane in a DEP domain–dependent manner to activate RAC1-JNK signaling, and DVL3 is required for cytoskeletal organization underlying blood–testis barrier integrity and spermatid polarity (PMID:39094673, PMID:30808893). DVL3 also translocates to the nucleus via its DIX and PDZ domains to regulate cell proliferation independently of β-catenin nuclear import, and pathogenic DVL3 frameshift variants that disrupt membrane recruitment and CK1-induced phosphorylation are associated with Robinow syndrome [PMID:35589804, PMID:bio_10.1101_2025.08.02.668297].

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 1997 High

    Establishing DVL3 as a human Dishevelled family member resolved whether the Drosophila Dsh signaling scaffold had a third mammalian paralogue and mapped it to chromosome 3q27.

    Evidence cDNA library screening, sequencing, chromosomal mapping, and Northern blot expression analysis

    PMID:9344861

    Open questions at the time
    • No functional assays performed
    • Relationship to WNT signaling not yet tested in mammalian cells
  2. 2012 High

    Demonstrating that DVL3 recruits IPMK to the membrane via its PDZ domain upon Wnt3a stimulation established DVL3 as an active scaffold that positions cofactors at the membrane for canonical WNT signaling.

    Evidence Co-immunoprecipitation, domain deletion mutants, membrane fractionation, CAAX-box rescue in Wnt3a-stimulated cells

    PMID:22940627

    Open questions at the time
    • Structural basis of DVL3–IPMK interaction unresolved
    • Whether IPMK recruitment is isoform-specific among DVL proteins not tested
  3. 2013 Medium

    Showing that DVL3 protein levels are controlled by AMPK/mTOR-dependent translational suppression and ubiquitin-proteasomal degradation revealed a metabolic-sensing layer of WNT pathway regulation.

    Evidence Proteasomal inhibitor rescue, in vivo ubiquitination assay, AMPK activator/inhibitor co-treatment in cervical cancer cells

    PMID:23301094

    Open questions at the time
    • E3 ubiquitin ligase responsible for DVL3 ubiquitination not identified
    • Whether this degradation mechanism is tissue-specific is unknown
  4. 2014 High

    Identifying DVL3 as part of an adaptor complex linking IGFIR to RAS-ERK signaling (with Shc, Grb2, SOS, DAB2) expanded DVL3 function beyond WNT to growth factor receptor signaling.

    Evidence Genetic screening, Co-IP of complex, in vitro and in vivo knockdown with MEK-ERK readouts, xenograft models

    PMID:25168481

    Open questions at the time
    • Direct binding partner within the complex not mapped at domain level
    • Whether DVL3 kinase-independent scaffold function suffices for IGFIR coupling is untested
  5. 2016 High

    Demonstrating that ALFY selectively targets DVL3 (not DVL1 or DVL2) aggregates for autophagic degradation established isoform-specific turnover as a mechanism to attenuate canonical WNT signaling, with loss of this control linked to primary microcephaly.

    Evidence Linkage analysis, whole-exome sequencing, Drosophila transgenic models, human cell autophagy assays, isoform-specific knockdown

    PMID:27008544

    Open questions at the time
    • Structural determinants of DVL3 isoform selectivity by ALFY unknown
    • Whether ALFY-DVL3 axis operates in adult brain homeostasis not tested
  6. 2019 Medium

    Two studies expanded DVL3's tissue-specific roles: DVL3 is required for Sertoli cell cytoskeletal organization and blood–testis barrier function, and DVL3 restrains inflammatory cytokine production in monocytes by stabilizing β-catenin to suppress NF-κB.

    Evidence In vivo testis-specific RNAi with tight junction permeability assays (spermatogenesis); DVL3 gain/loss-of-function with ELISA, NF-κB DNA binding, and murine endotoxemia model (inflammation)

    PMID:30808893 PMID:31884387

    Open questions at the time
    • Whether DVL3-specific PCP signaling or canonical signaling mediates the barrier phenotype is unclear
    • Mechanism of DVL3-mediated NF-κB suppression beyond β-catenin stabilization not dissected
  7. 2022 Medium

    Showing that DVL3 nuclear translocation (via DIX and PDZ domains) is required for its proliferative function independently of β-catenin nuclear import established a non-canonical nuclear role distinct from DVL1.

    Evidence Knockdown/rescue with domain deletion mutants, nuclear localization analysis, proliferation assays in myoblasts and rhabdomyosarcoma cells

    PMID:35589804

    Open questions at the time
    • Nuclear targets or transcriptional partners of DVL3 not identified
    • Whether nuclear DVL3 acts as a transcriptional coregulator or scaffold is unresolved
  8. 2024 Medium

    Two studies defined DVL3 post-translational regulation: WNT5B/FZD3 recruits DVL3 to the membrane via the DEP domain for RAC1-JNK non-canonical signaling, and PNPO oxidizes DVL3 at Met282 to aberrantly activate canonical WNT/β-catenin in myeloma.

    Evidence DEP domain deletion mutant analysis with RAC1/JNK activation (non-canonical); chemical probe pulldown identifying PNPO, DVL3-M282 mutagenesis, in vivo myeloma models (oxidation)

    PMID:39094673 PMID:39656865

    Open questions at the time
    • Whether Met282 oxidation affects DEP domain conformation or FZD binding is untested
    • Generality of PNPO-DVL3 oxidation beyond myeloma unknown
  9. 2025 Medium

    Pathogenic DVL3 frameshift variants associated with Robinow syndrome fail to redistribute to the membrane upon WNT3A stimulation and resist CK1-induced phosphorylation, providing a disease mechanism for DVL3 loss-of-function.

    Evidence Immunocytochemistry, TOPFlash reporter, CSNK1E phosphorylation assay in transfected cells (preprint)

    PMID:bio_10.1101_2025.08.02.668297

    Open questions at the time
    • Not yet peer-reviewed
    • Patient-derived cells not studied
    • Whether mutant DVL3 exerts dominant-negative effects on DVL1/DVL2 not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the identity of DVL3's nuclear transcriptional partners, the structural basis of the CK1 phospho-switch controlling DVL3-FZD detachment, the E3 ligase(s) mediating DVL3 proteasomal turnover, and whether DVL3-specific functions in PCP and canonical WNT signaling are separable in vivo.
  • No structural model of full-length DVL3
  • DVL3-specific conditional knockout phenotypes in mammals largely uncharacterized
  • Quantitative contribution of DVL3 versus DVL1/DVL2 to specific WNT branches in different tissues unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0140110 transcription regulator activity 2
Localization
GO:0005829 cytosol 3 GO:0005886 plasma membrane 3 GO:0005634 nucleus 2
Pathway
R-HSA-162582 Signal Transduction 7 R-HSA-1643685 Disease 3 R-HSA-1266738 Developmental Biology 2 R-HSA-9612973 Autophagy 1
Partners
ALFYCCNL1CSNK1EDAB2FZD3IPMKMEX3APNPO
Complex memberships
FZD3-DVL3-RAC1 (non-canonical WNT-PCP)IGFIR-Shc-Grb2-SOS-DAB2-DVL3 adaptor complex

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 DVL3 was cloned as a human homologue of Drosophila Dishevelled (Dsh), encoding a predicted 716 amino acid protein with 98% amino acid identity to mouse Dvl-3 and 49% to Drosophila Dsh, mapped to chromosomal locus 3q27, and shown to be widely expressed in human cell lines and tissues. cDNA library screening, sequencing, chromosomal mapping, Northern blot/expression analysis Biochemical and biophysical research communications High 9344861
2011 DVL3 mediates dopamine D2 receptor (D2DR) regulation of both Akt and Wnt/GSK-3β/β-catenin signaling; altering DVL3 levels in SH-SY5Y cells recapitulated changes in Akt phosphorylation and β-catenin levels observed after D2DR agonist/antagonist treatment, and co-immunoprecipitation revealed an association between GSK-3 and the D2DR complex modulated by DVL3. In vitro DVL3 overexpression/knockdown in SH-SY5Y cells, western blot, co-immunoprecipitation, pharmacological D2DR manipulation in rat brain The international journal of neuropsychopharmacology Medium 21777508
2012 DVL3 recruits IPMK (inositol polyphosphate multikinase) to the cell membrane via DVL3's PDZ domain and C-terminal proline-rich tail upon Wnt3a stimulation; membrane translocation of IPMK is required for its function in canonical Wnt signaling, and deletion of IPMK's N-terminal variable region abolishes membrane translocation and downstream signaling. Co-immunoprecipitation, deletion mutant analysis, membrane fractionation, Wnt3a stimulation assays, CAAX-box rescue experiment Cellular signalling High 22940627
2013 DVL3 is a positive regulator of Wnt/β-catenin signaling in cervical cancer; enforced DVL3 expression elevated β-catenin and cyclin D1; AMPK activators (metformin) reduce DVL3 protein via AMPK/mTOR-mediated inhibition of protein synthesis and partially through ubiquitin/proteasomal degradation, as demonstrated by restoration of DVL3 with proteasomal inhibitors and in vivo ubiquitination assay. Western blot, immunohistochemistry, forced expression/knockdown, proteasomal inhibitor rescue, in vivo ubiquitination assay, AMPK inhibitor co-treatment PloS one Medium 23301094
2014 DVL3 forms an adaptor complex linking IGFIR to RAS signaling, containing Shc, Grb2, SOS, and tumor suppressor DAB2; DVL3 blockade enhanced MEK-ERK activation and sensitized breast and prostate cancer cells to IGFIR inhibition in vitro and in vivo; dual DVL3 and DAB2 blockade synergized in ERK activation, indicating non-redundant roles. Genetic screening, Co-immunoprecipitation, in vitro and in vivo knockdown/pharmacologic blockade, MEK-ERK activation assays, xenograft models Cancer research High 25168481
2015 DVL3 is a direct target of miR-204-5p, established by luciferase reporter assay; DVL3 overexpression increases β-catenin and cyclin D1 expression, and DVL3 knockdown promotes adipogenic differentiation of human adipose-derived mesenchymal stem cells by suppressing Wnt/β-catenin signaling. Luciferase reporter assay, bioinformatics target prediction, overexpression/knockdown, western blot, adipogenic differentiation assays International journal of molecular medicine Medium 25847080
2016 ALFY, an autophagy scaffold protein, specifically targets DVL3 (but not DVL1 or DVL2) aggregates for autophagic degradation, thereby attenuating canonical Wnt signaling; loss of this function causes increased DVL3 aggregates, hyperactivated Wnt signaling, and primary microcephaly. Linkage analysis, whole exome sequencing, Drosophila transgenic model, human cell-based autophagy assays, isoform-specific knockdown PLoS genetics High 27008544
2018 DVL3 (and DVL1) translocates to the nucleus in human myoblasts and localizes to CYP19A1 promoters (pII, I.4, and I.1) in breast cancer cells; DVL1 and DVL3 loss of function differentially alters aromatase transcripts and estradiol production, revealing a nuclear transcriptional regulatory role for DVL3. ChIP (chromatin immunoprecipitation), subcellular fractionation, nuclear localization imaging, siRNA knockdown, aromatase transcript/E2 measurement Oncotarget Medium 30479694
2019 DVL3 (planar cell polarity protein) is required for Sertoli cell blood-testis barrier function and spermatid polarity in rat testis; DVL3 knockdown disrupts actin- and microtubule-based cytoskeleton organization in Sertoli cells, impairing tight junction permeability barrier and spermatid adhesion/transport. RNAi knockdown (Dvl1, Dvl2, Dvl3, and triple), in vivo testis knockdown, tight junction permeability assay, immunofluorescence, western blot, morphological analysis Cell death & disease Medium 30808893
2019 TLR4 activation by LPS promotes Wnt3a-Dvl3 signaling in monocytes; Dvl3 (downstream of Wnt3a) restrains inflammatory cytokine production (IL-12, IL-6, TNFα) by stabilizing β-catenin and suppressing NF-κB p65 phosphorylation and DNA binding; Dvl3 silencing enhances pro-inflammatory responses in vitro and in an in vivo endotoxemia model. siRNA knockdown, ectopic expression of DVL3/GSK3β/β-catenin, ELISA, qRT-PCR, western blot, NF-κB DNA binding assay, murine endotoxemia model Molecular immunology Medium 31884387
2020 DVL3 silencing in colorectal cancer cells attenuates Notch signaling by downregulating Notch intracellular domain (NICD) and its downstream targets, sensitizing cells to methotrexate and inhibiting cancer stem cell-like properties. siRNA knockdown, western blot (NICD and targets), functional assays (drug sensitivity, stemness markers) Pathology, research and practice Medium 32414668
2022 DVL3 nuclear localization is required for DVL3 to regulate proliferation in human myoblasts and rhabdomyosarcoma cells; DVL3's role in proliferation requires its DIX and PDZ domains (distinct from DVL1), and this activity is independent of markedly increased β-CATENIN nuclear translocation. Knockdown/rescue with domain deletion mutants, nuclear localization analysis, proliferation assays, myogenic differentiation assays Scientific reports Medium 35589804
2022 RNA-binding protein MEX3A physically interacts with DVL3 (demonstrated by co-immunoprecipitation) and stabilizes β-catenin, promoting Wnt/β-catenin signaling, EMT, and endometrial carcinoma cell growth and metastasis. Co-immunoprecipitation, immunofluorescence, in vitro and in vivo functional assays, western blot International journal of molecular sciences Medium 36614043
2024 WNT5B promotes non-canonical WNT-PCP signaling in NSCLC via FZD3-DVL3-RAC1-JNK; FZD3 recruits DVL3 to the membrane for phosphorylation in a WNT5B-dependent manner; deletion of the DEP domain of DVL3 abrogates DVL3 membrane recruitment and downstream RAC1/JNK activation. Co-immunoprecipitation (WNT5B/FZD3/DVL3 interactions), DEP domain deletion mutant analysis, in vitro and in vivo overexpression/knockdown, JNK/RAC1 activation assays Cellular signalling Medium 39094673
2024 PNPO (pyridoxine-5'-phosphate oxidase) oxidizes DVL3 at methionine 282 (DVL3M282), leading to abnormal activation of the Wnt/β-catenin pathway, promoting multiple myeloma cell proliferation and osteoclast differentiation; disrupting PNPO-DVL3 interaction with Eltrombopag inhibits this pathway. Chemical probe (celastrol) pulldown to identify PNPO as DVL3 interactor, site-directed mutagenesis (DVL3M282), in vivo mouse models, preliminary clinical data Advanced science Medium 39656865
2025 Wnt-induced CK1 multiphosphorylation of DVL3 causes a conformational phospho-switch in which charge accumulation proximal to the DEP domain promotes intramolecular coupling between DEP and the adjacent disordered region; this switch is mutually exclusive with FZD receptor binding, leading to DVL3 detachment from FZD after Wnt activation. Phospho-switch mutant panel, electrostatic analysis, in vitro phosphorylation assays, DVL3-FZD binding assays, functional Wnt/β-catenin reporter assays bioRxivpreprint Medium bio_10.1101_2025.09.10.675378
2025 Pathogenic DVL3 frameshifting variants (associated with Robinow syndrome) encode mutant proteins that fail to redistribute from cytoplasmic puncta to membrane upon WNT3A stimulation and fail to activate canonical WNT/β-catenin signaling in TOPFlash reporter assays; the mutant C-terminal tail also interferes with CSNK1E-induced phosphorylation. Immunocytochemistry (localization upon WNT3A stimulation), TOPFlash reporter assay, CSNK1E phosphorylation assay, in silico structural analysis, transfection-based in vitro system bioRxivpreprint Medium bio_10.1101_2025.08.02.668297
2025 BioID proximity interactomics identified the intracellular interactome of cytoplasmic DVL3 in the Wnt/PCP pathway context; DVL3-proximal proteins include RAI14, EPHA2, and PHACTR4, which were validated as essential Wnt/PCP components in zebrafish and connect the PCP receptor complex to actomyosin effectors. BioID proximity-dependent biotinylation, mass spectrometry, zebrafish loss-of-function (convergent extension, lateral organ orientation, melanoma migration assays) bioRxivpreprint Medium bio_10.1101_2025.01.15.633117
2025 DVL3 loss-of-function in isogenic iPSC-derived neural progenitor cells causes increased NPC proliferation, converging with CTNNB1 and PTEN ASD-risk variants on dysregulation of PBX1 as a downstream target. Isogenic iPSC-derived 2D NPC loss-of-function models, genetic epistasis, PBX1 overexpression rescue across DVL3/CTNNB1/PTEN variants bioRxivpreprint Low bio_10.1101_2025.03.12.642693
2025 E2F7 transcription factor directly activates DVL3 transcription (assessed by dual-luciferase reporter assay), thereby activating the Wnt signaling pathway to promote ESCC progression and cisplatin resistance; DVL3 overexpression reverses the effects of E2F7 knockdown on cisplatin sensitivity. Dual-luciferase reporter assay, gene expression analysis (qRT-PCR, western blot), siRNA knockdown, overexpression rescue, drug sensitivity assays World journal of surgical oncology Low 41327220
2026 CCNL1 directly interacts with DVL3 (demonstrated by co-immunoprecipitation), with the two proteins negatively correlated; CCNL1 overexpression inhibits DVL3 function and activates NF-κB signaling, while also promoting PI3K/AKT signaling, to drive breast cancer progression and paclitaxel resistance. Co-immunoprecipitation, western blot, plasmid transfection overexpression/rescue, Transwell/wound-healing assays, bioinformatics Molecular carcinogenesis Low 41632921

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PloS one 75 23301094
2016 ALFY-Controlled DVL3 Autophagy Regulates Wnt Signaling, Determining Human Brain Size. PLoS genetics 72 27008544
2015 miR-204-5p promotes the adipogenic differentiation of human adipose-derived mesenchymal stem cells by modulating DVL3 expression and suppressing Wnt/β-catenin signaling. International journal of molecular medicine 62 25847080
2016 AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity. Molecular medicine reports 43 28035400
2018 DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells. Oncotarget 40 30479694
2011 The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. The international journal of neuropsychopharmacology 39 21777508
2014 Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin. International journal of molecular sciences 38 24933634
2009 MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. Cancer letters 37 19815336
2014 Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. Cancer research 28 25168481
2019 Planar cell polarity protein Dishevelled 3 (Dvl3) regulates ectoplasmic specialization (ES) dynamics in the testis through changes in cytoskeletal organization. Cell death & disease 27 30808893
2019 TLR4 induced Wnt3a-Dvl3 restrains the intensity of inflammation and protects against endotoxin-driven organ failure through GSK3β/β-catenin signaling. Molecular immunology 24 31884387
1997 cDNA cloning of a human dishevelled DVL-3 gene, mapping to 3q27, and expression in human breast and colon carcinomas. Biochemical and biophysical research communications 22 9344861
2021 LncRNA testis-specific transcript, Y-linked 15 (TTTY15) promotes proliferation, migration and invasion of colorectal cancer cells via regulating miR-29a-3p/DVL3 axis. Cancer biomarkers : section A of Disease markers 18 33016900
2020 Silencing DVL3 defeats MTX resistance and attenuates stemness via Notch Signaling Pathway in colorectal cancer. Pathology, research and practice 18 32414668
2018 Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCF1 and LEF1 upregulation. Journal of cellular and molecular medicine 18 30468298
2018 Autosomal dominant Robinow syndrome associated with a novel DVL3 splice mutation. American journal of medical genetics. Part A 16 29575616
2021 LncRNA BLACAT1 Promotes Proliferation, Migration and Invasion of Prostate Cancer Cells via Regulating miR-29a-3p/DVL3 Axis. Technology in cancer research & treatment 15 33641528
2024 Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma. Phytomedicine : international journal of phytotherapy and phytopharmacology 14 38350242
2022 DVL1 and DVL3 require nuclear localisation to regulate proliferation in human myoblasts. Scientific reports 14 35589804
2018 Role and mechanism of Dvl3 in the esophageal squamous cell carcinoma. European review for medical and pharmacological sciences 14 30536315
2022 E2F1-activated LINC01224 drives esophageal squamous cell carcinoma cell malignant behaviors via targeting miR-6884-5p/DVL3 axis and activating Wnt/β-catenin signaling pathway. Pathology, research and practice 13 35576835
2022 RNA-Binding Protein MEX3A Interacting with DVL3 Stabilizes Wnt/β-Catenin Signaling in Endometrial Carcinoma. International journal of molecular sciences 13 36614043
2024 PNPO-Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-Catenin Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10 39656865
2012 Dvl3 translocates IPMK to the cell membrane in response to Wnt. Cellular signalling 10 22940627
2022 Circ_0101802 Facilitates Colorectal Cancer Progression Depending on the Regulation of miR-665/DVL3 Signaling. Biochemical genetics 9 35314912
2018 Dvl3 polymorphism interacts with life events and pro-inflammatory cytokines to influence major depressive disorder susceptibility. Scientific reports 9 30242173
2024 WNT5B promotes the malignant phenotype of non-small cell lung cancer via the FZD3-DVL3-RAC1-PCP-JNK pathway. Cellular signalling 8 39094673
2017 Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. BJU international 8 28107606
2024 Dishevelled Segment Polarity Protein 3 (DVL3) Induced by Bacterial LPS Promotes the Proliferation and Migration of Prostate Cancer Cells through the TLR4 Pathway. Archivos espanoles de urologia 5 38583012
2022 The Gender-Specific Interaction of DVL3 and GSK3β Polymorphisms on Major Depressive Disorder Susceptibility in a Chinese Han Population: A Case-Control Study. Oxidative medicine and cellular longevity 5 35126809
2022 Exosomal Dvl3 promoted the aggressive phenotypic transformation of RA-FLS via wnt pathway. Autoimmunity 5 35499309
2021 Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology letters 5 34691249
2023 Delivery of microRNA-423-5p by exosome from adipose-derived stem/stromal cells inhibits DVL3 to potentiate autologous fat graft survival through adipogenesis and inflammatory response. Human cell 3 38040867
2020 Retracted Article: Panax notoginseng saponins regulate VEGF to suppress esophageal squamous cell carcinoma progression via DVL3-mediated Wnt/β-catenin signaling. RSC advances 3 35497711
2023 Presenilin-2 knock-In mice show severe depressive behavior via DVL3 downregulation. CNS neuroscience & therapeutics 2 37501340
2020 Polymorphism and expression of the Dvl3 gene in the etiology of depressive disorder. Psychiatria polska 1 33038884
2026 CCNL1 Activates the NF-κB Pathway Through DVL3 Inhibition and PI3K/AKT Pathway Promotion in Breast Cancer. Molecular carcinogenesis 0 41632921
2025 E2F7 promotes ESCC progression and cisplatin resistance through transcriptional activation of DVL3 and the Wnt signaling pathway. World journal of surgical oncology 0 41327220
2022 [Effect of miR-204 targeted regulation of DVL3 gene in silica-induced mouse lung epithelial cells]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 0 35680573
2021 Retraction: Panax notoginseng saponins regulate VEGF to suppress esophageal squamous cell carcinoma progression via DVL3-mediated Wnt/β-catenin signaling. RSC advances 0 35427054